rs1137177

Variant summary

Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BA1

The NM_000037.4(ANK1):​c.2073C>T​(p.Gly691Gly) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.258 in 1,613,702 control chromosomes in the GnomAD database, including 57,216 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.21 ( 4337 hom., cov: 33)
Exomes 𝑓: 0.26 ( 52879 hom. )

Consequence

ANK1
NM_000037.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:8

Conservation

PhyloP100: -2.04

Publications

17 publications found
Variant links:
Genes affected
ANK1 (HGNC:492): (ankyrin 1) Ankyrins are a family of proteins that link the integral membrane proteins to the underlying spectrin-actin cytoskeleton and play key roles in activities such as cell motility, activation, proliferation, contact and the maintenance of specialized membrane domains. Multiple isoforms of ankyrin with different affinities for various target proteins are expressed in a tissue-specific, developmentally regulated manner. Most ankyrins are typically composed of three structural domains: an amino-terminal domain containing multiple ankyrin repeats; a central region with a highly conserved spectrin binding domain; and a carboxy-terminal regulatory domain which is the least conserved and subject to variation. Ankyrin 1, the prototype of this family, was first discovered in the erythrocytes, but since has also been found in brain and muscles. Mutations in erythrocytic ankyrin 1 have been associated in approximately half of all patients with hereditary spherocytosis. Complex patterns of alternative splicing in the regulatory domain, giving rise to different isoforms of ankyrin 1 have been described. Truncated muscle-specific isoforms of ankyrin 1 resulting from usage of an alternate promoter have also been identified. [provided by RefSeq, Dec 2008]
ANK1 Gene-Disease associations (from GenCC):
  • hereditary spherocytosis
    Inheritance: AR, AD Classification: DEFINITIVE, SUPPORTIVE, LIMITED Submitted by: ClinGen, Orphanet
  • hereditary spherocytosis type 1
    Inheritance: AR, AD Classification: STRONG, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, Laboratory for Molecular Medicine

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -19 ACMG points.

BP4
Computational evidence support a benign effect (REVEL=0.091).
BP6
Variant 8-41706167-G-A is Benign according to our data. Variant chr8-41706167-G-A is described in ClinVar as Benign. ClinVar VariationId is 261297.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-2.04 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.297 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ANK1NM_000037.4 linkc.2073C>T p.Gly691Gly synonymous_variant Exon 18 of 43 ENST00000289734.13 NP_000028.3 P16157-3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ANK1ENST00000289734.13 linkc.2073C>T p.Gly691Gly synonymous_variant Exon 18 of 43 1 NM_000037.4 ENSP00000289734.8 P16157-3

Frequencies

GnomAD3 genomes
AF:
0.210
AC:
31998
AN:
152086
Hom.:
4332
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0550
Gnomad AMI
AF:
0.283
Gnomad AMR
AF:
0.258
Gnomad ASJ
AF:
0.306
Gnomad EAS
AF:
0.0713
Gnomad SAS
AF:
0.311
Gnomad FIN
AF:
0.355
Gnomad MID
AF:
0.234
Gnomad NFE
AF:
0.269
Gnomad OTH
AF:
0.219
GnomAD2 exomes
AF:
0.259
AC:
64990
AN:
251096
AF XY:
0.264
show subpopulations
Gnomad AFR exome
AF:
0.0489
Gnomad AMR exome
AF:
0.295
Gnomad ASJ exome
AF:
0.319
Gnomad EAS exome
AF:
0.0680
Gnomad FIN exome
AF:
0.349
Gnomad NFE exome
AF:
0.270
Gnomad OTH exome
AF:
0.258
GnomAD4 exome
AF:
0.263
AC:
383995
AN:
1461498
Hom.:
52879
Cov.:
38
AF XY:
0.265
AC XY:
192847
AN XY:
727078
show subpopulations
African (AFR)
AF:
0.0463
AC:
1550
AN:
33468
American (AMR)
AF:
0.291
AC:
13000
AN:
44716
Ashkenazi Jewish (ASJ)
AF:
0.308
AC:
8038
AN:
26130
East Asian (EAS)
AF:
0.0824
AC:
3272
AN:
39700
South Asian (SAS)
AF:
0.315
AC:
27163
AN:
86242
European-Finnish (FIN)
AF:
0.343
AC:
18316
AN:
53368
Middle Eastern (MID)
AF:
0.257
AC:
1476
AN:
5754
European-Non Finnish (NFE)
AF:
0.266
AC:
295654
AN:
1111754
Other (OTH)
AF:
0.257
AC:
15526
AN:
60366
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.476
Heterozygous variant carriers
0
15705
31409
47114
62818
78523
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
9762
19524
29286
39048
48810
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.210
AC:
32005
AN:
152204
Hom.:
4337
Cov.:
33
AF XY:
0.214
AC XY:
15932
AN XY:
74404
show subpopulations
African (AFR)
AF:
0.0549
AC:
2280
AN:
41566
American (AMR)
AF:
0.258
AC:
3945
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.306
AC:
1061
AN:
3470
East Asian (EAS)
AF:
0.0710
AC:
367
AN:
5166
South Asian (SAS)
AF:
0.310
AC:
1493
AN:
4820
European-Finnish (FIN)
AF:
0.355
AC:
3761
AN:
10602
Middle Eastern (MID)
AF:
0.238
AC:
70
AN:
294
European-Non Finnish (NFE)
AF:
0.269
AC:
18305
AN:
67974
Other (OTH)
AF:
0.220
AC:
465
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.490
Heterozygous variant carriers
0
1183
2366
3549
4732
5915
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
344
688
1032
1376
1720
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.242
Hom.:
8995
Bravo
AF:
0.195
Asia WGS
AF:
0.221
AC:
767
AN:
3478
EpiCase
AF:
0.270
EpiControl
AF:
0.266

ClinVar

Significance: Benign
Submissions summary: Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary spherocytosis type 1 Benign:3
Nov 28, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Nov 10, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Spherocytosis Benign:1
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.79
CADD
Benign
2.1
DANN
Benign
0.46
PhyloP100
-2.0
PromoterAI
-0.12
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Mutation Taster
=97/3
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1137177; hg19: chr8-41563685; COSMIC: COSV55881658; API